These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 23795808)
1. Paradoxical oncogenesis: are all BRAF inhibitors equal? Menzies AM; Kefford RF; Long GV Pigment Cell Melanoma Res; 2013 Sep; 26(5):611-5. PubMed ID: 23795808 [TBL] [Abstract][Full Text] [Related]
2. New RAF kinase inhibitors in cancer therapy. Martin-Liberal J; Larkin J Expert Opin Pharmacother; 2014 Jun; 15(9):1235-45. PubMed ID: 24766074 [TBL] [Abstract][Full Text] [Related]
3. Dabrafenib and its potential for the treatment of metastatic melanoma. Menzies AM; Long GV; Murali R Drug Des Devel Ther; 2012; 6():391-405. PubMed ID: 23251089 [TBL] [Abstract][Full Text] [Related]
4. Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors. Escuin-Ordinas H; Li S; Xie MW; Sun L; Hugo W; Huang RR; Jiao J; de-Faria FM; Realegeno S; Krystofinski P; Azhdam A; Komenan SM; Atefi M; Comin-Anduix B; Pellegrini M; Cochran AJ; Modlin RL; Herschman HR; Lo RS; McBride WH; Segura T; Ribas A Nat Commun; 2016 Aug; 7():12348. PubMed ID: 27476449 [TBL] [Abstract][Full Text] [Related]
5. Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. Hecht M; Zimmer L; Loquai C; Weishaupt C; Gutzmer R; Schuster B; Gleisner S; Schulze B; Goldinger SM; Berking C; Forschner A; Clemens P; Grabenbauer G; Müller-Brenne T; Bauch J; Eich HT; Grabbe S; Schadendorf D; Schuler G; Keikavoussi P; Semrau S; Fietkau R; Distel LV; Heinzerling L Ann Oncol; 2015 Jun; 26(6):1238-1244. PubMed ID: 25762352 [TBL] [Abstract][Full Text] [Related]
7. BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma. Walter L; Heinzerling L Anticancer Res; 2018 Mar; 38(3):1335-1341. PubMed ID: 29491057 [TBL] [Abstract][Full Text] [Related]
8. Improved overall survival in melanoma with combined dabrafenib and trametinib. Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551 [TBL] [Abstract][Full Text] [Related]
9. Vemurafenib for the treatment of BRAF mutant metastatic melanoma. Martin-Liberal J; Larkin J Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114 [TBL] [Abstract][Full Text] [Related]
10. Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Spagnolo F; Ghiorzo P; Queirolo P Oncotarget; 2014 Nov; 5(21):10206-21. PubMed ID: 25344914 [TBL] [Abstract][Full Text] [Related]
11. Dabrafenib therapy for advanced melanoma. Trinh VA; Davis JE; Anderson JE; Kim KB Ann Pharmacother; 2014 Apr; 48(4):519-29. PubMed ID: 24259661 [TBL] [Abstract][Full Text] [Related]
13. Targeted therapies for cutaneous melanoma. Kee D; McArthur G Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943 [TBL] [Abstract][Full Text] [Related]
14. Overcoming metastatic melanoma with BRAF inhibitors. Hong S; Hong S; Han SB Arch Pharm Res; 2011 May; 34(5):699-701. PubMed ID: 21656352 [TBL] [Abstract][Full Text] [Related]
15. Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors. Lai F; Jiang CC; Farrelly ML; Zhang XD; Hersey P Melanoma Res; 2012 Jun; 22(3):244-51. PubMed ID: 22516966 [TBL] [Abstract][Full Text] [Related]
16. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma. Owen JL; Lopez IE; Desai SR J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671 [TBL] [Abstract][Full Text] [Related]
17. Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors. Anforth R; Blumetti TC; Clements A; Kefford R; Long GV; Fernandez-Peñas P Br J Dermatol; 2013 Dec; 169(6):1310-3. PubMed ID: 23870055 [TBL] [Abstract][Full Text] [Related]
18. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies. Gibney GT; Zager JS Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):893-9. PubMed ID: 23621583 [TBL] [Abstract][Full Text] [Related]
19. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505 [TBL] [Abstract][Full Text] [Related]
20. COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. Escuin-Ordinas H; Atefi M; Fu Y; Cass A; Ng C; Huang RR; Yashar S; Comin-Anduix B; Avramis E; Cochran AJ; Marais R; Lo RS; Graeber TG; Herschman HR; Ribas A Mol Oncol; 2014 Mar; 8(2):250-60. PubMed ID: 24345644 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]